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Abstract
We showed previously that nucleophosmin (NPM), a nucleolar
phosphoprotein, is recognized by sera from (NZW × BXSB)F1
(WB) mice, a model of systemic lupus erythematosus (SLE) and
anti-phospholipid syndrome. In the present study we analysed
the prevalence and kinetics of anti-NPM autoantibodies in WB
mice by a solid-phase ELISA with recombinant human (rh) NPM
as the antigen and showed that most male WB mouse sera had
anti-NPM antibodies that were responsible for their indirect
immunofluorescence staining pattern on Hep-2 cells. Anti-NPM
antibodies were significantly associated with anti-cardiolipin
(aCL) antibodies. This antibody profile mirrored that observed in
certain human SLE sera because anti-NPM antibodies were
detected in 28% of the sera from patients with SLE and were
similarly associated with aCL antibodies. The demonstration
that rhNPM bound to cardiolipin (CL) in vitro and increased the
CL-binding activity of a WB-derived aCL monoclonal antibody
indicates that NPM can interact with CL to form SLE-related
immunogenic particles that might be responsible for the
concomitant production of anti-NPM and aCL antibodies.
Introduction
(NZW × BXSB)F1 (WB) mice develop an autoimmune disease
whose histological and immunological manifestations resem-
ble those of human systemic lupus erythematosus (SLE) [1].
Male WB produce anti-nuclear antibodies (ANA), including
anti-deoxyribonucleic acid (DNA) autoantibodies and high lev-
els of anti-cardiolipin (aCL) antibodies that are thought to con-
tribute to the pathogenesis of myocardial infarction and
thrombocytopenia observed in these animals [2]. aCL antibod-
ies present in male WB mice require a plasma cofactor such
as β2-glycoprotein I (β2GPI), to bind to cardiolipin (CL) and
thus possess binding properties similar to those of aCL anti-
bodies observed in the serum of patients with SLE [3,4]. Male
WB mice are therefore considered an appropriate model for
the secondary anti-phospholipid syndrome associated with
SLE.
The precise nature of epitopes recognized by β2GPI-depend-
ent aCL antibodies remains a matter of debate. Some groups
consider that aCL antibodies do not recognize CL or β2GPI
alone but bind to either a CL-β2GPI complex [5] or cryptic
epitopes generated by their association [6]. Others think that
aCL antibodies bind to β2GPI in the absence of CL [7]. The
complexity of the interaction of anti-phospholipid antibodies
with their respective antigens is further illustrated by the dem-
onstration that β2GPI is not the unique cofactor involved in
their binding activity. Indeed, other phospholipid-binding pro-
teins have been described, such as prothrombin, protein C,
2D = two-dimensional; aCL = anti-cardiolipin; ANA = anti-nuclear antibodies; β2GPI = β2-glycoprotein I; BSA = bovine serum albumin; CL = cardi-
olipin; DTT = dithiothreitol; ELISA = enzyme-linked immunosorbent assay; FCS = fetal calf serum; mAb = monoclonal antibodies; MS = mass spec-
trometry; NPM = nucleophosmin; NTA = nitrilotriacetate; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; rhNPM = recombinant 
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protein S or annexin V, most of which participate in the coag-
ulation cascade [8,9].
We previously observed that WB mouse-derived monoclonal
antibodies (mAbs) selected for their capacities to react with
CL in the presence of FCS also reacted with nuclear antigens,
as shown by their nucleolar immunofluorescence-labelling pat-
tern on HEp-2 cells [10]. One of these mAbs, 4B7, reacted
with nucleophosmin (NPM; also known as B23), a nucleolar
protein involved in the assembly and transport of ribosomes
[11]. Subsequently, we showed by immunoscreening of a two-
dimensional (2D) PAGE-separated HL-60 cell protein map
with WB mouse sera and mass spectrometry (MS) that the
males of this strain mount an ordered autoimmune B-cell
response directed against various antigens, consistently
including NPM [12].
These observations led us to analyse further the prevalence
and kinetics of anti-NPM antibodies, their relationships with
aCL antibodies in WB mouse and human SLE sera and the
mechanisms that might account for the association between
these two antibody populations.
Materials and methods
Mice and sera
Female NZW and male BXSB mice were purchased, respec-
tively, from Bomholtgard Breeding and Research Center (Ry,
Denmark) and The Jackson Laboratory (Bar Harbor, ME,
USA), maintained in our animal facilities and crossbred to
obtain WB offspring. Control male CD1 mice were purchased
from Charles River Laboratories (Saint-Germain-sur-l'Arbresle,
France). All mice were housed in the same room and fed on
the same diet. Mice were bled every two months throughout
their lifetime. Sera were stored at -20°C until used. Sera from
(NZB × NZW)F1 and MRLlpr/lpr mice were also tested. Mouse
studies were approved by the animal Ethical Committee of
Normandy (ceean number 1004-27).
Patients and sera
Serum samples were collected from 82 patients with SLE that
met the criteria of the American College of Rheumatology. The
serological profile of these patients was analysed for ANA by
indirect immunofluorescence using HEp-2 cells, anti-DNA
antibodies by the Farr assay and anti-β2GPI by ELISA (Varelisa
β2-glycoprotein I IgG antibody EIA kit; Pharmacia Diagnostics,
Freiburg, Germany). Serum samples were obtained from 103
healthy blood donors (agreement 31/10/2003). The study
was approved by the Ethical Committee of Haute Normandie
(number 99135HP).
Indirect immunofluorescence assay
The immunofluorescence pattern of sera from WB mice and
patients with SLE was determined on Hep-2 cells as
described previously [10]. Inhibition experiments were per-
formed by preincubating an anti-NPM mouse mAb (Invitrogen
immunodetection, San Francisco, CA, USA), mouse and
patient sera for 1 hour with 20 µg of recombinant NPM.
Generation of mAb 4B7
Splenocytes from a four-month-old male WB mouse were
fused with P3 × 63Ag8.653 myeloma cell line and the result-
ing hybridoma secreting mAb 4B7 was selected on the basis
of the capacity of its supernatant to react with CL in ELISA.
mAb 4B7 was purified as described elsewhere [10].
Production and purification of recombinant human NPM 
in Escherichia coli
Total RNA was extracted from HL-60 cells by using TRIzol rea-
gent (Invitrogen, Eragny, France). The NPM cDNA was
obtained by transcription of oligo(dT) primer RNA with Molo-
ney murine leukaemia virus reverse transcriptase (Invitrogen).
An 879-base-pair DNA fragment was amplified from the cDNA
by PCR with the primers NPM-NdeI (5' -GGAATTCCATAT-
GGAAGATTCGATGGACATGGAC-3', sense) and NPM-
BamHI (5' -CCGGATCCTTACTTGTCATCGTCGTCCTTG-
TAGTCCGTACGAAGAGACTTCCTCCACTGCC-3', anti-
sense) designed to create a FLAG tag followed by a stop
codon and a BamHI site. The purified PCR product was
cloned into Nde-BamHI-digested pET-15b (Novagen, Madi-
son, WI, USA) downstream from the histidine tag. The result-
ing plasmid was transfected into E. coli BL21(DE3) pLysE
(Novagen, Darmstadt, Germany). Expression was induced by
incubation with isopropyl β-D-thiogalactoside (final concentra-
tion 1 mM) for 2.5 hours. E. coli pellets were suspended and
lysed in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole, 1 mg/ml lysozyme and 1 mg/ml protease inhibitors,
pH 8). The suspension was sonicated at 40% intensity for 2.5
minutes (Vibra Cell; Bioblock Scientific, Illkirch, France) and
centrifuged at 7,000 g for 15 minutes at 4°C. The supernatant
was subjected to repeated aspiration and expulsion through a
fine needle to mechanically break DNA and then passed
through 0.22 µm filter. Batch purification was performed with
Ni2+-nitrilotriacetate (NTA)-Sepharose (Qiagen, Hilden, Ger-
many). The resin was washed with buffer (50 mM NaH2PO4, 1
M NaCl, 20 mM imidazole, 20% (v/v) ethanol, pH 8) until UV
absorbance at 280 nm became negative. The recombinant
human nucleophosmin (rhNPM) was eluted with 50 mM
NaH2PO4, 300 mM NaCl, 150 mM imidazole, pH 8. The
rhNPM-enriched fractions were dialysed against water and
then freeze-dried. This purification was performed for a sec-
ond time with the same protocol. The protein concentration
was determined with the Bradford protein assay kit (Bio-Rad
Laboratories Inc., Marnes-la-Coquette, France) and the yield
was about 2.5 mg per 150 ml of E. coli culture. Purity was con-
trolled by SDS-PAGE analysis with a 10% polyacrylamide gel
followed by western blotting with an anti-histidine-tag mAb
(Sigma-Aldrich Corp., St Louis, MO, USA). rhNPM was used
to detect anti-NPM antibodies, including those present in
mouse sera, because they were previously shown to bind
human NPM expressed by a human cell line [12] and there isAvailable online http://arthritis-research.com/content/7/6/R1394
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95% identity between human NPM and NO38, the murine
equivalent of human NPM.
ELISA for anti-NPM autoantibodies
High-binding plates (96-well, Microlon; Dutscher, Issy-les-
Moulineaux, France) were coated with 10 µg/ml purified
rhNPM in 0.05 M carbonate-bicarbonate buffer (pH 9.5) and
incubated overnight at 4°C. After being washed in PBS con-
taining 0.05% Tween, wells were blocked with PBS contain-
ing 5% (w/v) BSA for 2 hours at 23°C. Plates were washed
three times with 0.05% PBS-Tween, followed by the addition
to duplicate wells of mouse or human of sera, diluted 1:50 or
1:100, respectively, in diluting buffer (1% (w/v) BSA-PBS),
and then incubated for 2 hours at room temperature. After
being washed, biotin-conjugated goat anti-mouse IgG (Caltag
Laboratories, Hamburg, Germany) diluted 1:10,000 was
added, and incubated for 1 hour at room temperature. After
three washes, alkaline phosphatase-conjugated streptavidin
(1:10,000 dilution; Caltag Laboratories) was added and incu-
bated for 10 minutes at room temperature. After three washes,
plates were revealed with p-nitrophenyl phosphate (Sigma).
The absorbance at 405 nm (A405) was read. Horseradish per-
oxidase-conjugated goat anti-human IgG (Sigma) was added
and revealed with 3,3',5,5'-tetramethylbenzidine (Sigma). A405
was read. Positive mouse sera were defined as those giving an
A405 reading greater than the mean value plus 2 SD of sera
from 60 normal control CD1 male mice. Positive human sera
were defined as those giving an A405 reading greater than the
mean value plus 3 SD of sera from 103 healthy controls.
ELISA for anti-CL antibodies
Each well of polystyrene microtitre plates (96-well; Luxlon,
Nemours, France) was coated with 50 µl of bovine heart CL
(10 µg/ml) in absolute alcohol. The plates were incubated
overnight at 4°C to allow the ethanol to evaporate. After block-
ing of non-specific binding sites by incubation with 10% FCS,
the plates were washed with PBS and incubated with sera
diluted in FCS. The plates were washed three times followed
by incubation with alkaline phosphatase-conjugated goat anti-
mouse IgG (Rockland, Gilbertsville, PA, USA) or with horse-
radish peroxidase-conjugated goat anti-human IgG. Reactivity
was determined as described above. Positive mouse sera
were defined as above, whereas positive human sera were
defined as those giving an A405 reading of more than 20 immu-
noglobulin G phospholipid international units (GPLU).
NPM binding to CL
To determine whether NPM reacts with CL, CL-coated plates
were incubated with different rhNPM concentrations for 1
hour at room temperature. After blocking of non-specific bind-
ing sites with 0.5% gelatin, plates were washed three times
with PBS. Anti-histidine or anti-FLAG (Sigma-Aldrich) mAb
was added and incubated for 1 hour. After three washes, alka-
line phosphatase-conjugated goat anti-mouse IgG was added
and revealed with p-nitrophenyl phosphate.
Biacore analysis
The Biacore Biosensor system (Biacore, Uppsala, Sweden)
was used to study the interaction between rhNPM and CL.
Vesicles were prepared by drying 5 mg of CL under vacuum
and hydrating the lipid in 1 ml of PBS as described previously
[13]. The vesicles (400 µg/ml) were captured on the surface
of sensor chip L1, consisting of dextran modified with
lipophilic compounds. We successively injected into the sys-
tem 10 µl of 20 mM CHAPS, 150 µl of vesicles and 10 µl of
10 mM NaOH to stabilize the baseline, yielding about 4,000
to 5,000 resonance units (RU) of bound antigen. Then differ-
ent rhNPM concentrations (100 to 500 µg/ml) were injected
and the sensor chip was regenerated with 20 mM CHAPS.
Haemoglobin (Sigma) and human recombinant envoplakin
produced in our laboratory were used as controls. In a second
series of experiments, rhNPM was immobilized on the surface
of sensor chip NTA, allowing the binding of histidine-tagged
proteins. In brief, we injected 20 µl of 500 µM NiCl2 and then
40 µl of 200 µg/ml NPM, which yielded about 1,500 RU of
antigen. The CL vesicles (400 µg/ml) were injected and the
sensor chip was regenerated with 350 mM EDTA.
Effect of rhNPM on aCL-binding activity
To examine the effect of rhNPM on aCL-binding activity, puri-
fied 4B7 mAb (0.8 mg/ml) was incubated on CL-coated plates
in the presence or absence of NPM, in an ELISA as described
above.
Preparation of HL-60 cell-protein extract for 2D PAGE
Human promyelocytic leukaemia cell line (American Type Cul-
ture Collection, Manassas, VA, USA) was grown at 37°C in a
humidified atmosphere (95% air, 5% CO2) in 50 ml of RPMI
1640 (Invitrogen, Eragny, France), supplemented with 10%
FCS Sigma), antibiotics (Invitrogen) and 1 mM sodium pyru-
vate (Sigma). Cells were washed three times with PBS and
isolated by centrifugation at 15,000 g for 5 minutes at room
temperature. HL-60 cells (2 × 108) were suspended in 10%
(v/v) trichloroacetic acid, 0.12% (w/v) dithiothreitol (DTT) and
stored overnight at -20°C. Cells were centrifuged at 4°C for
30 minutes at 15,000 g. Cell pellets were suspended again in
0.12% (w/v) DTT and kept at -20°C for 1 hour before being
centrifuged. Dry pellets were suspended in lysis buffer (9 M
urea, 2% (w/v) CHAPS, 1% (w/v) DTT, 2% (v/v) protease
inhibitors (Sigma)) and then centrifuged at 4°C for 20 minutes
at 1,500 g. The protein content was determined with the Plu-
sOne 2D Quant kit (Amersham, Buckinghamshire, UK).
This lysate was subjected to 2D PAGE as previously
described [12]. The immunoreactive spots were detected with
human sera, diluted 1:100. After being washed, membranes
were incubated with alkaline phosphatase-conjugated goat
anti-human IgG (Amersham) and revealed with Nitro Blue
Tetrazolium salt and 5-bromo-4-chloroindol-3-yl phosphate
substrate (Roche, Meylan, France).Arthritis Research & Therapy    Vol 7 No 6    Lartigue et al.
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Protein identification
The immunoreactive spots were excised from polyacrylamide
gels with Ettan Spot Picker (Amersham) and digested by
trypsin (proteomics grade; Sigma) with Ettan Digester (Amer-
sham). Samples were analysed by matrix-assisted laser des-
orption/ionization-time-of-flight MS to obtain peptide mass
information. Spectra obtained were compared with those reg-
istered in protein databases (SWISS-PROT and NCBInr).
Data were matched against the databases with the use of the
MS-Fit program (accessible through ProteinProspector).
Statistical analysis
Absorbances of sera obtained from male and female WB mice
of the same age were compared with the Mann-Whitney U-
test. The percentages of different antibodies in the sera of
patients with SLE were compared by using a χ2 test. The rela-
tionship between the titres of different antibodies in mouse
sera was evaluated with Spearman's correlation test.
Results
Male WB mouse sera frequently react with NPM
To determine the prevalence of anti-NPM antibodies, sera col-
lected from normal CD1 (n = 54) and WB lupus-prone mice
at different times of life were analysed by solid-phase ELISA
using rhNPM. As shown in Fig. 1a, anti-NPM antibodies were
present early in life in male WB mice and were detected in
more than 75% of sera from animals more than three months
old. Anti-NPM antibodies appeared later in female WB mice
(25% at 3 months), were less frequent (40% at 4 to 6 months)
and gave low A405 values. The A405 of male WB sera were sig-
nificantly higher than those of control mouse sera at each
period (P = 0.01) and tested dilution (Fig. 1b), whereas female
WB A405 values differed significantly from normal mouse sera
only at four months (P = 0.03). All anti-NPM antibody-positive
mouse sera, tested by immunoblotting on 2D PAGE-sepa-
rated HL-60 cell-protein map, bound to the native human
NPM, thereby confirming their previously reported reactivity
with this nucleolar autoantigen [12]. Anti-NPM positive mouse
sera gave a nucleolar staining pattern on Hep-2 cells by indi-
rect immunofluorescence analysis similar to that observed
with an anti-NPM mouse mAb (Fig. 2a,c). Preincubation of the
mAb and mouse sera with recombinant NPM abrogated the
nucleolar staining (Fig. 2b,d).
NPM-binding activity in other mouse strains
We then tested WB parental strains, female NZW and male
BXSB mice, but no reactivity against NPM was observed. Sim-
ilarly, offspring of NZB and NZW mice also did not develop
anti-NPM antibodies. In contrast, anti-NPM antibodies were
present in 60% of 20 sera from MRLlpr/lpr mice more than three
months old.
Anti-NPM and aCL antibodies are associated in male WB 
mice
Because WB lupus-prone mice are also characterized by aCL
antibody production, we looked for an association between
anti-NPM and aCL antibodies in their sera. Indeed, anti-NPM
and aCL antibodies were found to be associated in sera from
three-month-old male WB mice (χ2 = 18.14; P < 0.0001), and
their A405 values were positively correlated (r = 0.750; P <
0.0001; Fig. 3a). Similarly, A405 values of anti-NPM and aCL
antibodies in sera from MRLlpr/lpr mice more than three months
old were positively correlated (r = 0.585; P < 0.01; Fig. 3b).
Figure 1
Nucleophosmin-binding activity of WB lupus-prone and control mouse  sera Nucleophosmin-binding activity of WB lupus-prone and control mouse 
sera. (a) Sera from male (◆ ) and female (■ ) WB mice, and from male 
CD1 (▲ ) mice, collected during months 1 to 2, 2 to 3, 3 to 4 and 4 to 
6, were tested in solid-phase ELISA. The horizontal dotted line repre-
sents the cutoff value (mean A405 of controls + 2 SD). Sera with A405 < 
0.522 were considered negative. (* P = 0.03, ** P = 0.01, *** P = 
0.0001; Mann-Whitney test). (b) Different dilutions of male (◆ ) and 
female (■ ) WB and male (▲ ) CD1 mouse sera collected at 3.5 months 
were tested in ELISA.Available online http://arthritis-research.com/content/7/6/R1394
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Anti-NPM antibodies are present in patients with SLE 
and are associated with aCL antibodies
The demonstration that anti-NPM antibodies are frequently
produced in male WB mice prompted us to search for anti-
NPM antibodies in the sera of 82 patients with SLE. Indeed,
23 (28%) of these sera were positive for anti-NPM antibody
(Fig. 4) and the antibodies seemed to be more frequent
(although not significantly) in males than in females (5/9 ver-
sus 18/73; Table 1). These anti-NPM antibody-positive SLE
sera were analysed by immunoblotting on HL-60 cell protein
separated by 2D PAGE (Fig. 5a); most of them (80%) reacted
consistently with a spot of molecular mass (36 kDa) and pI
(4.5) that had the same coordinates as that recognized by
male WB mice and was characteristic of NPM (Fig. 5c). The
immunoreactive spots bound by human and mouse sera were
excised and analysed by matrix-assisted laser desorption/ioni-
zation-time-of-flight MS and corresponded to NPM (Fig. 5b, d).
Anti-NPM antibody-positive SLE sera yielded homogeneous
nuclear and nucleolar staining on Hep-2 cells by indirect
immunofluorescence analysis (Fig. 2e). The nucleolar staining
disappeared when sera were preincubated with recombinant
NPM (Fig. 2f).
aCL antibodies were detected in 32 (39%) of the sera from
patients with SLE. Pertinently, as in WB mice, the analysis of
the distribution of anti-NPM and aCL antibodies in these SLE
sera (Table 1) indicates that these autoantibodies were asso-
ciated (χ2 = 9.2; P = 0.002). In contrast, ANA, anti-DNA and
anti-β2GPI antibodies rates did not differ significantly between
anti-NPM-positive and anti-NPM-negative patients. Interest-
ingly, of the 23 anti-NPM-positive sera, 18 (78%) did not react
with  β2GPI; conversely, of the 12 anti-β2GPI-aCL-positive
Figure 2
Immunofluorescence staining pattern of anti-nucleophosmin-positive  WB mouse and SLE sera on HEp-2 cells Immunofluorescence staining pattern of anti-nucleophosmin-positive 
WB mouse and SLE sera on HEp-2 cells. An anti-nucleophosmin (anti-
NPM) mouse mAb and anti-NPM antibody-positive mouse sera gave a 
nucleolar pattern (a,c). Anti-NPM-antibody-positive systemic lupus ery-
thematosus (SLE) sera yielded homogeneous nuclear and nucleolar 
staining (e). The nucleolar staining was abrogated when the mAb and 
sera from mouse (b,d) or patient (f) were previously incubated with 10 
µg of recombinant human nucleophosmin.
Figure 3
Correlation between anti-nucleophosmin and anti-cardiolipin antibodies  in lupus mice Correlation between anti-nucleophosmin and anti-cardiolipin antibodies 
in lupus mice. A positive correlation between anti-nucleophosmin and 
anti-cardiolipin antibody reactivities in 38 sera from male WB mice (a) 
and 20 sera from MRLlpr/lpr mice (b) more than 3 months old.Arthritis Research & Therapy    Vol 7 No 6    Lartigue et al.
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sera, only three were positive for anti-NPM, suggesting that
the presence of these two autoantibody populations is mutu-
ally exclusive.
NPM interacts in vitro with CL
The demonstration that anti-NPM and aCL antibodies were
associated in WB mice and certain patients with SLE was
reminiscent of the previously described association between
anti-β2GPI and aCL antibodies; it led us to ask whether NPM
could bind to CL. CL-coated plates were incubated with
increasing concentrations of rhNPM, which was revealed with
an anti-histidine or anti-FLAG mAb. Figure 6a shows that NPM
bound to CL-coated wells in a dose-dependent manner. This
binding was confirmed by Biacore analysis. CL vesicles were
captured on the surface of sensor chip L1 and NPM was
injected at a concentration of 400 µg/ml. Figure 7 shows that
CL vesicles bound to NPM (Fig. 7a, with a difference of 3,550
RU) but did not bind to irrelevant proteins (haemoglobin and
envoplakin; Fig. 7b). Similarly, NPM captured on an NTA sen-
sor chip bound CL vesicles, giving a response of 2,885 RU
(Fig. 7c).
NPM increases the CL binding of a murine mAb
The demonstration that NPM could bind to CL prompted us to
study the effect of rhNPM on the CL-binding activity of purified
4B7, an aCL mAb derived from a WB mouse whose serum
contained both aCL and anti-NPM antibodies [10]. Indeed, in
ELISA, 4B7 reactivity with CL increased markedly in the pres-
ence of NPM, which therefore acted as a cofactor (Fig. 6b).
Similarly, with the use of sensor chip L1 coated with CL vesi-
cles or CL vesicles plus NPM, the binding of 4B7 to the chip
was enhanced 1.5-fold (2,578 versus 3,989 RU; Fig. 8).
Discussion
NPM (B23) is an abundant nucleolar phosphoprotein with
multiple functions: the assembly and/or transport of ribosomes
[11], chaperone activities [14] and a regulatory role in cell pro-
liferation [15,16]. NPM was previously shown to be targeted
by antibodies produced in patients with either non-organ-spe-
cific autoimmune diseases [17-19] or cancer, namely hepato-
cellular and breast carcinoma [20,21].
Figure 4
Nucleophosmin-binding activity of sera from patients with SLE Nucleophosmin-binding activity of sera from patients with SLE. (a) Sera 
from patients with systemic lupus erythematosus (SLE) (◆ ) or from 
healthy controls (-) were analysed by ELISA using recombinant human 
nucleophosmin. The dotted line represents the cutoff value (mean A405 
of controls + 3 SD). Sera giving an A405 < 0.286 were considered neg-
ative. (b) Different dilutions of serum from an SLE patient (◆ ) and a 
control (■ ) were tested in ELISA.
Table 1
Demographic and serological profiles of patients with SLE
Characteristic SLE patients Anti-NPM 
antibodies
(n = 82) Positive (n = 23) Negative (n = 59)
Age, years 
(mean ± SD)
38.3 ± 12.3 39.8 ± 14.9 37.8 ± 11.5
Females 73 (89.0) 18* 55
Males 9 (10.8) 5* 4
aCL 32 (39) 15 (65.2)** 17 (28.8)**
ANA-positive 66 (80.5) 23 (100) 43 (72.8)
Anti-DNA 46 (56) 13 (56.5) 33 (55.9)
Anti-β2GPI 15 (18.3) 5 (21.7) 10 (16.9)
Anti-β2GPI-CL+ 12 (14.6) 3 (13) 9 (15.2)
aCL, anti-cardiolipin; ANA, anti-nuclear antibodies; β2GPI, β2-
glycoprotein I; CL, cardiolipin; NPM, nucleophosmin; SLE, systemic 
lupus erythematosus. Values are n (%) unless indicated otherwise.
* χ2 = 2.4; P = 0.12. ** χ2 = 9.2; P = 0.002.Available online http://arthritis-research.com/content/7/6/R1394
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By using a sensitive ELISA with rhNPM as the antigen, we
showed that anti-NPM antibodies are present in most male
WB lupus-prone mice and are therefore a constant feature of
the antibody response in these animals: anti-NPM positivity
appeared early in life, increased with age, and peaked at three
to four months, before death. In contrast to our previous obser-
vations obtained by immunoblot analysis of 2D gel-separated
NPM [12], this sensitive ELISA enabled us to detect these
antibodies in female WB mice too, although later, less fre-
quently and initially at lower A405 values. Pertinently, anti-NPM
antibodies in male WB mice were consistently associated with
aCL, and both antibody populations appeared concomitantly,
as shown by sequential analyses of WB sera. Anti-NPM anti-
bodies could also be detected in MRLlpr/lpr mice and again
were significantly associated with aCL antibodies, which are
frequently produced by this lupus mouse strain. This antibody
pattern mirrored that observed in certain human SLE sera.
Indeed, anti-NPM antibodies were present in 28% of our 82
patients with SLE; they were more frequent in males and were
significantly associated with aCL antibodies. The association
of anti-NPM and aCL antibodies was first suggested by Li and
colleagues [17]. Indeed, in their analysis of 164 sera obtained
from patients with various autoimmune diseases selected by
the presence of anti-nucleolar antibodies, 6 had anti-NPM and
aCL antibodies and SLE. However, our results, showing that
anti-NPM antibodies are constantly detected in WB mice and
frequently observed in patients with SLE, demonstrate that
anti-NPM antibodies constitute a frequent and new marker in
mouse and human lupus, establish a clear relationship
between anti-NPM and aCL antibodies and finally define a
subset of patients with aCL antibodies.
The association of aCL and anti-NPM antibodies in WB lupus-
prone mice and patients with SLE might be explained by two
different mechanisms: first, cross-reactivity due to the expres-
sion of a shared epitope by CL and NPM, or second, the ability
of NPM to interact with CL to form an immunogenic complex
able to induce the two antibody populations and/or a unique
antibody population able to react with both NPM and CL (dual
reactivity), as reported for lupus-related antigen particles [22-
24]. The former hypothesis is not supported by the presence
of anti-NPM-positive/aCL-negative sera and, conversely, aCL-
Figure 5
Immunoblot analyses of sera positive for anti-nucleophosmin antibody Immunoblot analyses of sera positive for anti-nucleophosmin antibody. (a,c) Anti-nucleophosmin antibody obtained respectively from a patient with 
systemic lupus erythematosus (SLE) (a) and a male WB mouse (c) using a 2D PAGE-separated HL-60 cell protein map as the substrate. (b,d) Mass 
spectra of the proteins bound by the SLE (b) and mouse (d) serum.Arthritis Research & Therapy    Vol 7 No 6    Lartigue et al.
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positive/anti-NPM-negative sera and by the demonstration
that anti-NPM antibodies induced by immunization of normal
mice do not react with CL (data not shown); this conclusion
was also reached by Li and colleagues [17], who showed that
affinity-purified anti-NPM antibodies from SLE sera did not
bind to CL. We therefore tested the second hypothesis, which
proposed that lupus-related antigens are made of physically
linked epitopes, such as DNA-histones [22] or Sm-DNA
[23,24] and implies that NPM is able to bind to CL and behave
as an aCL antibody cofactor. Plasmon resonance analysis of
Figure 6
Binding of rhNPM to cardiolipin and effects of nucleophosmin on cardi- olipin-binding activity of 4B7 mAb Binding of rhNPM to cardiolipin and effects of nucleophosmin on cardi-
olipin-binding activity of 4B7 mAb. (a) Cardiolipin was coated on plas-
tic plates and incubated with various concentrations of recombinant 
human nucleophosmin (rhNPM). (b) mAb 4B7 was incubated on cardi-
olipin-coated plates in the absence or presence of rhNPM. Bars repre-
sent the mean A405 of duplicate experiments and error bars represent 
SD.
Figure 7
Biacore analysis of recombinant human nucleophosmin (rhNPM)-cardi- olipin interaction Biacore analysis of recombinant human nucleophosmin (rhNPM)-cardi-
olipin interaction. (a,b) Cardiolipin vesicles were captured on the sur-
face of the sensor chip L1 and rhNPM (a), haemoglobin or envoplakin 
(b) were injected. (c) rhNPM was immobilized on the surface of the 
Ni2+-nitrilotriacetate sensor chip and cardiolipin vesicles were injected.Available online http://arthritis-research.com/content/7/6/R1394
R1402
rhNPM-CL interaction clearly showed that NPM binds to CL in
vitro to form complexes. This binding might be attributed to the
functional N-terminal domain, which contains a high density of
hydrophobic residues involved in chaperone activity [25]. The
same technology enabled us to show that the reactivity of 4B7
mAb to NPM-CL complexes was markedly enhanced in com-
parison with its reactivity to either NPM or CL alone,
suggesting that 4B7 is representative of mAbs exhibiting a
dual specificity similar to that previously reported for certain
anti-histone murine mAbs, whose binding activity is increased
by DNA [22,26]. In human SLE sera, such autoantibodies
probably exist but their identification remains elusive because
of the polyclonal nature of sera, which may simultaneously
contain monoreactive anti-NPM and anti-CL antibodies.
These results could also lead us to consider that NPM acts as
an aCL cofactor, at least in this murine model of lupus. So far,
several cofactors of anti-phospholipid antibodies have been
described; most of them are soluble proteins involved in coag-
ulation [27,28]. We have showed here that a nuclear autoan-
tigen can behave as an aCL cofactor. This observation raises
important questions: is NPM the unique nuclear autoantigen
acting as an aCL cofactor? When and where does NPM inter-
act with CL to form an immunogenic complex able to initiate
antibody responses to both proteins? NPM is an abundant
nuclear protein [29] that can translocate to the cytoplasm
[30]. Recently, it was found to be localized in the cell
membrane and to be a component of the fructose lysine-spe-
cific receptor expressed by monocyte-like cell lines [31]. Thus,
NPM could well interact with anionic phospholipids at the cell
membrane to form a typical lupus-related immunogenic com-
plex, which could be released. Experiments are under way to
determine the cellular localization of NPM in different catego-
ries of cells and during various cellular processes, such as
apoptosis, which is thought to have a major role in the break-
age of B cell tolerance in SLE [32]. The answer to these ques-
tions will help to explain the high frequency of anti-
phospholipid antibodies in patients with SLE and to identify
other nuclear autoantigens able to behave as an aCL cofactor.
Another important objective is to precisely define the sensitiv-
ity and specificity of anti-NPM antibodies for lupus and to
determine whether their presence is correlated with disease
activity or clinical manifestations in patients with SLE. Such an
analysis is under way in a large series of patients with SLE and
various autoimmune diseases and will help to clarify the dis-
ease significance of this autoantibody population.
Conclusion
In this study we show that anti-NPM antibodies constitute a
frequent marker in WB and MRLlpr/lpr lupus-prone mice and in
human SLE, establish a clear relationship between anti-NPM
and aCL antibodies and define a subset of patients with aCL
antibodies. The demonstration that NPM binds to CL in vitro
and increases the CL-binding activity of a WB-derived aCL
mAb indicates that NPM can interact with CL to form SLE-
related immunogenic particles that might be responsible for
the concomitant production of anti-NPM and aCL antibodies.
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Figure 8
Biacore analysis of binding of 4B7 mAb to cardiolipin-nucleophosmin  complexes Biacore analysis of binding of 4B7 mAb to cardiolipin-nucleophosmin 
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